Medicare Coverage Issues Manual - Transmittal 145
Section 35-101, Treatment of Actinic Keratosis (AK), permits coverage for the destruction of actinic keratoses. Coverage is extended for surgical or medical treatment methods, including but not limited to cryosurgery with liquid nitrogen, curettage, excision, and photodynamic therapy (PDT), without restrictions based on patient or lesion characteristics. Medicare contractors retain discretion to determine the number of visits considered reasonable and necessary to treat these lesions.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: October 26, 2001
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.